Presentation is loading. Please wait.

Presentation is loading. Please wait.

Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy  Brian P. Vickery, MD, Amy M. Scurlock, MD, Michael Kulis,

Published byAdrián Szilágyi Modified over 5 years ago

Similar presentations

Presentation on theme: "Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy  Brian P. Vickery, MD, Amy M. Scurlock, MD, Michael Kulis,"— Presentation transcript:

1 Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy 
Brian P. Vickery, MD, Amy M. Scurlock, MD, Michael Kulis, PhD, Pamela H. Steele, CPNP, Janet Kamilaris, RN, Jelena P. Berglund, PhD, Caitlin Burk, BA, Anne Hiegel, RN, Suzanna Carlisle, RN, Lynn Christie, RD, Tamara T. Perry, MD, Robbie D. Pesek, MD, Saira Sheikh, MD, Yamini Virkud, MD, MA, P. Brian Smith, MD, MHS, MPH, Mohamed H. Shamji, PhD, Stephen R. Durham, MD, Stacie M. Jones, MD, A. Wesley Burks, MD  Journal of Allergy and Clinical Immunology  Volume 133, Issue 2, Pages e6 (February 2014) DOI: /j.jaci Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2 Fig 1 Conduct of the study.
Journal of Allergy and Clinical Immunology  , e6DOI: ( /j.jaci ) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

3 Fig 2 Food challenge results. Shown are the cumulative amounts of protein successfully ingested before onset of symptoms in TSs (blue circles) and TFs (red circles). Each circle represents 1 subject. Journal of Allergy and Clinical Immunology  , e6DOI: ( /j.jaci ) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

4 Fig 3 Skin prick test (SPT) results. A, Average mean wheal diameters at baseline by outcome. B, Mean wheal diameters over time by outcome. Lines represent median values. *P < .05 and **P < .01. ns, Not significant. Journal of Allergy and Clinical Immunology  , e6DOI: ( /j.jaci ) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

5 Fig 4 Peanut- and component-specific serum IgE levels during OIT. A-C, Longitudinal peanut-specific (Fig 4, A) and Ara h 1– and Ara h 2–specific (Fig 4, B) IgE levels are shown for individual subjects by outcome and for all components in all subjects (Fig 4, C). D and E, Peanut-specific IgE/total IgE ratio is shown for all subjects (Fig 4, D) and for individual subjects by outcome (Fig 4, E). All point estimates are medians with interquartile ranges (Fig 4, C). *P < .05, **P < .01, and ***P < ns, Not significant. Journal of Allergy and Clinical Immunology  , e6DOI: ( /j.jaci ) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

6 Fig 5 Peanut-specific serum IgG levels, IgG4 levels, and IgE/IgG4 ratios during OIT. A, Median values for all subjects’ longitudinal peanut-specific IgG and IgG4 and Ara h 2–specific IgG4 levels are shown. B, Peanut-specific IgG4 levels are shown for subjects by outcome. C and D, Peanut-specific IgE/IgG4 ratios are shown for all subjects (Fig 5, C) and by outcome (Fig 5, D). Lines represent medians. *P < .05 and **P < .01. ns, Not significant. Journal of Allergy and Clinical Immunology  , e6DOI: ( /j.jaci ) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

7 Fig 6 Serum from subjects receiving peanut OIT inhibits FAB. A, FAB data are shown for all subjects in gray, with the mean linear regression slope coefficient indicated by the black line and 95% CIs indicated by the hatched line. B, FAB by outcome is shown, with lines representing medians. **P < .01. Journal of Allergy and Clinical Immunology  , e6DOI: ( /j.jaci ) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

8 Fig E1 Regulatory T-cell numbers are not statistically different between the TS and TF groups at the time of SOFC. CD4+CD25+ forkhead box protein 3 (FoxP3)+ regulatory T cells are shown as a percentage of CD4+ T cells. Regulatory T-cell numbers were measured from PBMCs cultured with peanut proteins at the time of SOFC. Journal of Allergy and Clinical Immunology  , e6DOI: ( /j.jaci ) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

9 Fig E2 The discriminative potential of baseline factors on OIT outcome. Receiver operating characteristic curves are shown in the figure. Optimal cut points for each factor are shown in tabular form below in descending order by area under the curve (AUC). PN, Peanut; SPT, skin prick test. Journal of Allergy and Clinical Immunology  , e6DOI: ( /j.jaci ) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

10 Fig E3 The discriminative potential of end-of-study factors on OIT outcome. Receiver operating characteristic curves are shown in the figure. Optimal cut points for each factor shown in tabular form below in descending order by area under the curve (AUC). PN, Peanut; SPT, skin prick test. Journal of Allergy and Clinical Immunology  , e6DOI: ( /j.jaci ) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Download ppt "Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy  Brian P. Vickery, MD, Amy M. Scurlock, MD, Michael Kulis,"

Similar presentations

Immunologic features of infants with milk or egg allergy enrolled in an observational study (Consortium of Food Allergy Research) of food allergy  Scott.

Immunologic features of infants with milk or egg allergy enrolled in an observational study (Consortium of Food Allergy Research) of food allergy  Scott.
Skin prick test responses and allergen-specific IgE levels as predictors of peanut, egg, and sesame allergy in infants  Rachel L. Peters, MPH, Katrina.

Skin prick test responses and allergen-specific IgE levels as predictors of peanut, egg, and sesame allergy in infants  Rachel L. Peters, MPH, Katrina.
Repeated low-dose intradermal allergen injection suppresses allergen-induced cutaneous late responses  Giuseppina Rotiroti, MD, Mohamed Shamji, PhD, Stephen.

Repeated low-dose intradermal allergen injection suppresses allergen-induced cutaneous late responses  Giuseppina Rotiroti, MD, Mohamed Shamji, PhD, Stephen.
Diagnosing peanut allergy with skin prick and specific IgE testing

Diagnosing peanut allergy with skin prick and specific IgE testing
Corinne A. Keet, MD, MS, Pamela A

Corinne A. Keet, MD, MS, Pamela A
A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy  Satya D. Narisety,

A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy  Satya D. Narisety,
SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial  Stephen.

SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial  Stephen.
Sublingual immunotherapy for peanut allergy: A randomized, double-blind, placebo- controlled multicenter trial  David M. Fleischer, MD, A. Wesley Burks,

Sublingual immunotherapy for peanut allergy: A randomized, double-blind, placebo- controlled multicenter trial  David M. Fleischer, MD, A. Wesley Burks,
Omalizumab facilitates rapid oral desensitization for peanut allergy

Omalizumab facilitates rapid oral desensitization for peanut allergy
Alison M. Hofmann, MD, Amy M. Scurlock, MD, Stacie M

Alison M. Hofmann, MD, Amy M. Scurlock, MD, Stacie M
Increased peanut-specific IgA levels in saliva correlate with food challenge outcomes after peanut sublingual immunotherapy  Michael Kulis, PhD, Katie.

Increased peanut-specific IgA levels in saliva correlate with food challenge outcomes after peanut sublingual immunotherapy  Michael Kulis, PhD, Katie.
Stacie M. Jones, MD, Scott H. Sicherer, MD, A

Stacie M. Jones, MD, Scott H. Sicherer, MD, A
Jay A. Lieberman, MD, Faith R. Huang, MD, Hugh A

Jay A. Lieberman, MD, Faith R. Huang, MD, Hugh A
Ann-Marie M. Schoos, MD, PhD, Jacob D

Ann-Marie M. Schoos, MD, PhD, Jacob D
Efficacy and Safety of AR101 in Oral Immunotherapy for Peanut Allergy: Results of ARC001, a Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical.

Efficacy and Safety of AR101 in Oral Immunotherapy for Peanut Allergy: Results of ARC001, a Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical.
Peanut oral immunotherapy results in increased antigen-induced regulatory T-cell function and hypomethylation of forkhead box protein 3 (FOXP3)  Aleena.

Peanut oral immunotherapy results in increased antigen-induced regulatory T-cell function and hypomethylation of forkhead box protein 3 (FOXP3)  Aleena.
Dorothy M. Ryan, MD, Stephen J. Fowler, MD, Robert M. Niven, MD 

Dorothy M. Ryan, MD, Stephen J. Fowler, MD, Robert M. Niven, MD 
The component-specific to total IgE ratios do not improve peanut and hazelnut allergy diagnoses  Linus Grabenhenrich, MD, MPH, Lars Lange, MD, Magdalena.

The component-specific to total IgE ratios do not improve peanut and hazelnut allergy diagnoses  Linus Grabenhenrich, MD, MPH, Lars Lange, MD, Magdalena.
A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy  Robert A.

A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy  Robert A.
SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial  Stephen.

SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial  Stephen.

Similar presentations

Ads by Google